Cyclooxygenase-2-derived prostaglandin E2 promotes human cholangiocarcinoma cell growth and invasion through EP1 receptor-mediated activation of the epidermal growth factor receptor and Akt.
about
MicroRNA-26a promotes cholangiocarcinoma growth by activating β-cateninA triple combination of atorvastatin, celecoxib and tipifarnib strongly inhibits pancreatic cancer cells and xenograft pancreatic tumorsRecent advances in the regulation of cholangiocarcinoma growthAntagonism of the prostaglandin E2 EP1 receptor in MDCK cells increases growth through activation of Akt and the epidermal growth factor receptor.New insights on cholangiocarcinoma.Screening and identification of dietary oils and unsaturated fatty acids in inhibiting inflammatory prostaglandin E2 signaling in fat stromal cells.PGE2 signaling and its biosynthesis-related enzymes in cholangiocarcinoma progression.Cyclooxygenase-2 transactivates the epidermal growth factor receptor through specific E-prostanoid receptors and tumor necrosis factor-alpha converting enzyme.Role of the prostaglandin E2/E-prostanoid 2 receptor signalling pathway in TGFβ-induced mice mesangial cell damage.Secretin inhibits cholangiocarcinoma growth via dysregulation of the cAMP-dependent signaling mechanisms of secretin receptor.Microsomal prostaglandin E synthase-1 inhibits PTEN and promotes experimental cholangiocarcinogenesis and tumor progression.JNK contributes to the tumorigenic potential of human cholangiocarcinoma cells through the mTOR pathway regulated GRP78 induction.Molecular profiles of parvalbumin-immunoreactive neurons in the superior temporal cortex in schizophrenia.RET/PTC-induced cell growth is mediated in part by epidermal growth factor receptor (EGFR) activation: evidence for molecular and functional interactions between RET and EGFR.EP4 receptor stimulation down-regulates human eosinophil function.Immunodetection of cyclooxygenase-2 (COX-2) is restricted to tissue macrophages in normal rat liver and to recruited mononuclear phagocytes in liver injury and cholangiocarcinomaInterleukin-6-driven progranulin expression increases cholangiocarcinoma growth by an Akt-dependent mechanismNon-steroidal anti-inflammatory drugs for cancer prevention: promise, perils and pharmacogenetics.The tyrosine kinase c-Met contributes to the pro-tumorigenic function of the p38 kinase in human bile duct cholangiocarcinoma cellsProstaglandin E2 receptor distribution and function in the gastrointestinal tract.The challenge of cholangiocarcinoma: dissecting the molecular mechanisms of an insidious cancer.Cholangiocarcinoma: advances in pathogenesis, diagnosis, and treatment.Role of ErbB family receptor tyrosine kinases in intrahepatic cholangiocarcinomaCyclooxygenase-2 prevents fas-induced liver injury through up-regulation of epidermal growth factor receptor.Prostaglandin E2 stimulates β1-integrin expression in hepatocellular carcinoma through the EP1 receptor/PKC/NF-κB pathway.Essential fatty acids and their metabolites as modulators of stem cell biology with reference to inflammation, cancer, and metastasis.Molecular mechanisms of target recognition by lipid GPCRs: relevance for cancer.Role of the embryonic protein SOX2 in cholangiocarcinoma.Epidemiology and Risk Factors of Cholangiocarcinoma.Aspirin may prevent cholangiocarcinoma: a case-control study from the United kingdom.RNAi-mediated knockdown of cyclooxygenase2 inhibits the growth, invasion and migration of SaOS2 human osteosarcoma cells: a case control study.Simvastatin stimulates apoptosis in cholangiocarcinoma by inhibition of Rac1 activity.The in vitro and in vivo anti-tumor effect of KO-202125, a sauristolactam derivative, as a novel epidermal growth factor receptor inhibitor in human breast cancer.Suppression of invasive properties of colorectal carcinoma SW480 cells by 15-hydroxyprostaglandin dehydrogenase gene.Cyclooxygenase-2 overexpression abrogates the antiproliferative effects of TGF-beta.Modulation of Stat3 activation by the cytosolic phospholipase A2alpha and cyclooxygenase-2-controlled prostaglandin E2 signaling pathway.Aspirin use and the risk of cholangiocarcinoma.Multiple protein kinase pathways mediate amplified IL-6 release by human lung fibroblasts co-exposed to nickel and TLR-2 agonist, MALP-2.Involvement of COX-2/PGE(2) Pathway in the Upregulation of MMP-9 Expression in Pancreatic Cancer.Upregulation of the EP1 receptor for prostaglandin E2 promotes skin tumor progression.
P2860
Q28263940-59DB5053-6472-4F27-A85C-BCA0397CF741Q33778138-032D8BB8-FE9F-486F-BF7E-E7C12A7A21E8Q33994814-D47B2338-0AED-4276-BA3D-CE0F58B34342Q34131084-8661575B-4FA8-41E9-995B-D487BDB5B2F4Q34391135-E9BD8B73-35F1-4709-8B8A-09AE37E7521FQ34400103-1B03C6E7-39E7-4957-9103-874E0FAB4358Q34420486-84881AE6-EDC7-42D3-AFD2-3174A6A99447Q34637939-5D68EA01-0E71-4C20-BB67-A7A5E47D76D2Q34706829-BAFFAA22-8D8B-4013-A309-E0E35CAE292EQ35012302-2605B594-576A-44AC-A7DF-E88ED1810791Q35028164-B5AA01F4-2007-476A-8A89-91FAEA6F92BFQ35109010-CFE5310B-5563-4BDE-9D2C-6874E799E5F3Q35120498-9BD79CA0-E075-4D55-92D7-36B5579D6538Q35124840-83EC9C15-75ED-4099-A146-D6E71B87CDFBQ35332774-C8CA9D05-D7AC-4300-80A4-FCCECE1B9771Q35683401-39A729F3-3AE0-4414-BE5A-08B8A189C984Q35841978-5D06FAD7-2CF1-46ED-B0AF-1AF532AA0411Q36402212-53A336FA-7765-4181-9C5F-25C79EA8C7DCQ36407783-13209B0B-0D19-4D9D-B836-39F7D7E24606Q36611067-8FB6E9BD-1775-438D-8394-EFD021B2B9C9Q36683019-192CD0D0-567B-4459-9D22-C3BCB6839469Q36900063-D525FED3-9F0B-49A2-BE4B-1E79AE27E291Q37351498-DA5D75A3-5738-43B3-9B79-D426B1031A82Q37378968-5495C2A8-8C20-4199-BD6C-8F6B668EE404Q37734894-676BACB4-1E1E-4C39-ADA2-D2D2B3FA97AEQ37946729-77BA4ADE-1324-4079-A2A2-45999D33EFBAQ38660494-A1F78848-3C30-4263-A634-4F2FD027552AQ38987475-378E6D03-737B-4441-95E1-56ADE3F1C513Q39147308-C003C93F-BD81-4D91-AF92-911CC3382755Q39249181-33ECF8A1-DB9A-4605-8173-D149F6E06125Q39581230-AE4FB3B6-BCC6-4454-8580-7422D1D35F28Q39589202-55AA3C91-2D2B-4BDC-8F74-B32163A4FC27Q39612495-A10F6411-DAEC-4CA6-82BC-DE1F86644B46Q39912197-2BE3A63D-1D98-42DF-8131-287EE5D5D893Q40063666-A2CA8E79-4A63-4156-B4E1-EC910D77C99AQ40264460-78D1EAAF-167F-433C-9E47-A6B23E7E94BAQ40873283-98E1A719-2447-47D0-BF83-3B6DEE287917Q42111049-632AB8FF-B8D5-4BAC-AB65-C2FF699A2684Q42145392-418D5A3F-55A5-4135-B31C-B42EB992A30FQ42483046-AEEE64B7-235A-4888-8B07-776923835672
P2860
Cyclooxygenase-2-derived prostaglandin E2 promotes human cholangiocarcinoma cell growth and invasion through EP1 receptor-mediated activation of the epidermal growth factor receptor and Akt.
description
2005 nî lūn-bûn
@nan
2005 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
name
Cyclooxygenase-2-derived prost ...... rowth factor receptor and Akt.
@ast
Cyclooxygenase-2-derived prost ...... rowth factor receptor and Akt.
@en
Cyclooxygenase-2-derived prost ...... rowth factor receptor and Akt.
@nl
type
label
Cyclooxygenase-2-derived prost ...... rowth factor receptor and Akt.
@ast
Cyclooxygenase-2-derived prost ...... rowth factor receptor and Akt.
@en
Cyclooxygenase-2-derived prost ...... rowth factor receptor and Akt.
@nl
prefLabel
Cyclooxygenase-2-derived prost ...... rowth factor receptor and Akt.
@ast
Cyclooxygenase-2-derived prost ...... rowth factor receptor and Akt.
@en
Cyclooxygenase-2-derived prost ...... rowth factor receptor and Akt.
@nl
P2860
P356
P1476
Cyclooxygenase-2-derived prost ...... rowth factor receptor and Akt.
@en
P2093
P2860
P304
24053-24063
P356
10.1074/JBC.M500562200
P407
P577
2005-04-26T00:00:00Z